Elanco Animal Health Incorporated (NYSE: ELAN) Stock Competitors & Peer Comparison

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, TAK has a market cap of 65.8B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while TAK trades at $21.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas TAK's P/E ratio is 15.11. In terms of profitability, ELAN's ROE is -0.02%, compared to TAK's ROE of +0.05%. Regarding short-term risk, ELAN is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TAK's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, TEVA has a market cap of 49.6B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while TEVA trades at $42.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas TEVA's P/E ratio is 14.54. In terms of profitability, ELAN's ROE is -0.02%, compared to TEVA's ROE of +0.06%. Regarding short-term risk, ELAN is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TEVA's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, HLN has a market cap of 40.2B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while HLN trades at $9.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas HLN's P/E ratio is 18.69. In terms of profitability, ELAN's ROE is -0.02%, compared to HLN's ROE of +0.10%. Regarding short-term risk, ELAN is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check HLN's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ZTS has a market cap of 32.8B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ZTS trades at $79.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ZTS's P/E ratio is 12.07. In terms of profitability, ELAN's ROE is -0.02%, compared to ZTS's ROE of +0.76%. Regarding short-term risk, ELAN is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ZTS's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, VTRS has a market cap of 22.9B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while VTRS trades at $19.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas VTRS's P/E ratio is 7.90. In terms of profitability, ELAN's ROE is -0.02%, compared to VTRS's ROE of -0.04%. Regarding short-term risk, ELAN is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check VTRS's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ELAN's ROE is -0.02%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ELAN is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ITCI's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, RDY has a market cap of 12.4B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while RDY trades at $14.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas RDY's P/E ratio is 31.71. In terms of profitability, ELAN's ROE is -0.02%, compared to RDY's ROE of +0.07%. Regarding short-term risk, ELAN is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check RDY's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ELAN's ROE is -0.02%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ELAN is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check CTLT's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ALKS has a market cap of 7.7B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ALKS trades at $45.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ALKS's P/E ratio is 48.34. In terms of profitability, ELAN's ROE is -0.02%, compared to ALKS's ROE of -0.00%. Regarding short-term risk, ELAN is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ALKS's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, AMRX has a market cap of 7B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while AMRX trades at $20.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas AMRX's P/E ratio is 22.37. In terms of profitability, ELAN's ROE is -0.02%, compared to AMRX's ROE of +1.32%. Regarding short-term risk, ELAN is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check AMRX's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while LNTH trades at $100.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas LNTH's P/E ratio is 16.91. In terms of profitability, ELAN's ROE is -0.02%, compared to LNTH's ROE of +0.22%. Regarding short-term risk, ELAN is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check LNTH's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, INDV has a market cap of 4.5B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while INDV trades at $36.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas INDV's P/E ratio is 9.94. In terms of profitability, ELAN's ROE is -0.02%, compared to INDV's ROE of -3.53%. Regarding short-term risk, ELAN is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check INDV's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, BHC has a market cap of 3.1B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while BHC trades at $8.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas BHC's P/E ratio is 2.09. In terms of profitability, ELAN's ROE is -0.02%, compared to BHC's ROE of +0.59%. Regarding short-term risk, ELAN is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check BHC's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, HCM has a market cap of 2.7B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while HCM trades at $15.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas HCM's P/E ratio is 147.29. In terms of profitability, ELAN's ROE is -0.02%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ELAN is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check HCM's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, RGC has a market cap of 2.6B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while RGC trades at $5.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas RGC's P/E ratio is -531.50. In terms of profitability, ELAN's ROE is -0.02%, compared to RGC's ROE of -1.61%. Regarding short-term risk, ELAN is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check RGC's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ELAN's ROE is -0.02%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ELAN is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check DCPH's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, PRGO has a market cap of 2.2B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while PRGO trades at $15.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas PRGO's P/E ratio is 6.34. In terms of profitability, ELAN's ROE is -0.02%, compared to PRGO's ROE of -0.68%. Regarding short-term risk, ELAN is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check PRGO's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ELAN's ROE is -0.02%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, ELAN is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check AVDL's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while TRLV trades at $11.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas TRLV's P/E ratio is -4.69. In terms of profitability, ELAN's ROE is -0.02%, compared to TRLV's ROE of -0.46%. Regarding short-term risk, ELAN is more volatile compared to TRLV. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TRLV's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while EMBCV trades at $33.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ELAN's ROE is -0.02%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ELAN is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check EMBCV's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ELAN's ROE is -0.02%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, ELAN is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check DVAX's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ALVO has a market cap of 1.7B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ALVO trades at $4.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ALVO's P/E ratio is -8.15. In terms of profitability, ELAN's ROE is -0.02%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, ELAN is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ALVO's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas TARO's P/E ratio is 30.05. In terms of profitability, ELAN's ROE is -0.02%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ELAN is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TARO's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ETON trades at $56.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ETON's P/E ratio is 148.58. In terms of profitability, ELAN's ROE is -0.02%, compared to ETON's ROE of +1.05%. Regarding short-term risk, ELAN is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check ETON's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ANIP has a market cap of 1.5B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ANIP trades at $67.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ANIP's P/E ratio is 8.20. In terms of profitability, ELAN's ROE is -0.02%, compared to ANIP's ROE of +0.20%. Regarding short-term risk, ELAN is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ANIP's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, SUPN has a market cap of 1.5B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while SUPN trades at $26.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas SUPN's P/E ratio is -34.55. In terms of profitability, ELAN's ROE is -0.02%, compared to SUPN's ROE of -3.53%. Regarding short-term risk, ELAN is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check SUPN's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, PCRX has a market cap of 1.5B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while PCRX trades at $36.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas PCRX's P/E ratio is 14.01. In terms of profitability, ELAN's ROE is -0.02%, compared to PCRX's ROE of +0.06%. Regarding short-term risk, ELAN is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check PCRX's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while PAHC trades at $32.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas PAHC's P/E ratio is 11.25. In terms of profitability, ELAN's ROE is -0.02%, compared to PAHC's ROE of +0.27%. Regarding short-term risk, ELAN is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check PAHC's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while CRON trades at $3.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas CRON's P/E ratio is 18.51. In terms of profitability, ELAN's ROE is -0.02%, compared to CRON's ROE of +0.05%. Regarding short-term risk, ELAN is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check CRON's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ALVOW has a market cap of 1.3B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ALVOW trades at $0.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ALVOW's P/E ratio is 20.44. In terms of profitability, ELAN's ROE is -0.02%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, ELAN is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ALVOW's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, AMPH has a market cap of 1.2B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while AMPH trades at $28.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas AMPH's P/E ratio is 9.72. In terms of profitability, ELAN's ROE is -0.02%, compared to AMPH's ROE of +0.13%. Regarding short-term risk, ELAN is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check AMPH's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, HROW has a market cap of 1B. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while HROW trades at $26.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas HROW's P/E ratio is -27.19. In terms of profitability, ELAN's ROE is -0.02%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ELAN is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check HROW's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ELAN's ROE is -0.02%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ELAN is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check PETQ's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, COLL has a market cap of 787.5M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while COLL trades at $24.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas COLL's P/E ratio is 3.04. In terms of profitability, ELAN's ROE is -0.02%, compared to COLL's ROE of +0.12%. Regarding short-term risk, ELAN is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check COLL's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, IRWD has a market cap of 725.4M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while IRWD trades at $4.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas IRWD's P/E ratio is 5.63. In terms of profitability, ELAN's ROE is -0.02%, compared to IRWD's ROE of -0.81%. Regarding short-term risk, ELAN is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check IRWD's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, EVO has a market cap of 600.3M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while EVO trades at $1.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas EVO's P/E ratio is -2.39. In terms of profitability, ELAN's ROE is -0.02%, compared to EVO's ROE of -0.27%. Regarding short-term risk, ELAN is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check EVO's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ELAN's ROE is -0.02%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ELAN is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check BDSI's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, TKNO has a market cap of 481.9M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while TKNO trades at $7.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas TKNO's P/E ratio is -25.19. In terms of profitability, ELAN's ROE is -0.02%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ELAN is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check TKNO's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, EOLS has a market cap of 452.8M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while EOLS trades at $6.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas EOLS's P/E ratio is -21.71. In terms of profitability, ELAN's ROE is -0.02%, compared to EOLS's ROE of +1.03%. Regarding short-term risk, ELAN is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check EOLS's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, AQST has a market cap of 452.3M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while AQST trades at $3.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas AQST's P/E ratio is -5.54. In terms of profitability, ELAN's ROE is -0.02%, compared to AQST's ROE of +2.55%. Regarding short-term risk, ELAN is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check AQST's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, KMDA has a market cap of 416.6M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while KMDA trades at $7.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas KMDA's P/E ratio is 19.00. In terms of profitability, ELAN's ROE is -0.02%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ELAN is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check KMDA's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ACB has a market cap of 331.4M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ACB trades at $5.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ACB's P/E ratio is -3.78. In terms of profitability, ELAN's ROE is -0.02%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ELAN is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ACB's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, TLRY has a market cap of 326.5M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while TLRY trades at $2.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas TLRY's P/E ratio is -2.09. In terms of profitability, ELAN's ROE is -0.02%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, ELAN is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TLRY's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, EBS has a market cap of 309.7M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while EBS trades at $6.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas EBS's P/E ratio is 4.19. In terms of profitability, ELAN's ROE is -0.02%, compared to EBS's ROE of -0.61%. Regarding short-term risk, ELAN is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check EBS's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ELAN's ROE is -0.02%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ELAN is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ALIM's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, CGC has a market cap of 275.8M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while CGC trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas CGC's P/E ratio is -1.46. In terms of profitability, ELAN's ROE is -0.02%, compared to CGC's ROE of -0.37%. Regarding short-term risk, ELAN is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check CGC's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ELAN's ROE is -0.02%, compared to LNDC's ROE of +5.75%. Regarding short-term risk, ELAN is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check LNDC's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, LFCR has a market cap of 241.3M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while LFCR trades at $6.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas LFCR's P/E ratio is -5.01. In terms of profitability, ELAN's ROE is -0.02%, compared to LFCR's ROE of +3.82%. Regarding short-term risk, ELAN is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check LFCR's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ELAN's ROE is -0.02%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ELAN is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TYHT's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, SIGA has a market cap of 223.5M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while SIGA trades at $3.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas SIGA's P/E ratio is 11.52. In terms of profitability, ELAN's ROE is -0.02%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ELAN is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check SIGA's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, GLAS has a market cap of 182.6M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while GLAS trades at $2.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas GLAS's P/E ratio is -3.71. In terms of profitability, ELAN's ROE is -0.02%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, ELAN is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check GLAS's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas REPH's P/E ratio is -8.04. In terms of profitability, ELAN's ROE is -0.02%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ELAN is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check REPH's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas THTX's P/E ratio is -28.83. In terms of profitability, ELAN's ROE is -0.02%, compared to THTX's ROE of +0.36%. Regarding short-term risk, ELAN is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check THTX's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ELAN's ROE is -0.02%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ELAN is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ASRT's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, DERM has a market cap of 126.4M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while DERM trades at $4.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas DERM's P/E ratio is -20.36. In terms of profitability, ELAN's ROE is -0.02%, compared to DERM's ROE of -0.20%. Regarding short-term risk, ELAN is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check DERM's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, OGI has a market cap of 123.6M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while OGI trades at $0.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas OGI's P/E ratio is 1.97. In terms of profitability, ELAN's ROE is -0.02%, compared to OGI's ROE of +0.21%. Regarding short-term risk, ELAN is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check OGI's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, CRDL has a market cap of 119.3M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while CRDL trades at $1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas CRDL's P/E ratio is -3.94. In terms of profitability, ELAN's ROE is -0.02%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, ELAN is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check CRDL's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ELAN's ROE is -0.02%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ELAN is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check SCTL's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, BGM has a market cap of 111.5M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while BGM trades at $8.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas BGM's P/E ratio is -1.83. In terms of profitability, ELAN's ROE is -0.02%, compared to BGM's ROE of -0.05%. Regarding short-term risk, ELAN is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check BGM's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ORGO has a market cap of 104.6M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ORGO trades at $0.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ORGO's P/E ratio is 27.11. In terms of profitability, ELAN's ROE is -0.02%, compared to ORGO's ROE of -0.47%. Regarding short-term risk, ELAN is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check ORGO's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas PROC's P/E ratio is 1.53. In terms of profitability, ELAN's ROE is -0.02%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ELAN is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check PROC's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ELAN's ROE is -0.02%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ELAN is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check OPTN's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ELAN's ROE is -0.02%, compared to ZOM's ROE of -0.14%. Regarding short-term risk, ELAN is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ZOM's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ELAN's ROE is -0.02%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, ELAN is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check GRVI's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, CPIX has a market cap of 78.1M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while CPIX trades at $5.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas CPIX's P/E ratio is -13.02. In terms of profitability, ELAN's ROE is -0.02%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ELAN is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check CPIX's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ZYBT has a market cap of 70.6M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ZYBT trades at $1.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ZYBT's P/E ratio is -7.45. In terms of profitability, ELAN's ROE is -0.02%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, ELAN is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check ZYBT's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ELAN's ROE is -0.02%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ELAN is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ZYNE's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ELAN's ROE is -0.02%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ELAN is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check SSIC's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ELAN's ROE is -0.02%, compared to VLNS's ROE of N/A. Regarding short-term risk, ELAN is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check VLNS's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ELAN's ROE is -0.02%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, ELAN is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check DRRX's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, TLPH has a market cap of 55M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while TLPH trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas TLPH's P/E ratio is -3.93. In terms of profitability, ELAN's ROE is -0.02%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, ELAN is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check TLPH's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ELAN's ROE is -0.02%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, ELAN is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check JUPW's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, INCR has a market cap of 39.7M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while INCR trades at $3.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas INCR's P/E ratio is -3.53. In terms of profitability, ELAN's ROE is -0.02%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ELAN is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check INCR's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas QLI's P/E ratio is -4.92. In terms of profitability, ELAN's ROE is -0.02%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ELAN is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check QLI's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, RMTI has a market cap of 31.3M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while RMTI trades at $7.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas RMTI's P/E ratio is -5.79. In terms of profitability, ELAN's ROE is -0.02%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, ELAN is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check RMTI's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ELAN's ROE is -0.02%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ELAN is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check HEXO's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, SHPH has a market cap of 25.2M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while SHPH trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas SHPH's P/E ratio is -0.25. In terms of profitability, ELAN's ROE is -0.02%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, ELAN is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check SHPH's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, CPHI has a market cap of 24.3M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while CPHI trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas CPHI's P/E ratio is -1.31. In terms of profitability, ELAN's ROE is -0.02%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, ELAN is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check CPHI's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ELAN's ROE is -0.02%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ELAN is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check CYTH's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, TXMD has a market cap of 19.7M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while TXMD trades at $1.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas TXMD's P/E ratio is 86.60. In terms of profitability, ELAN's ROE is -0.02%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ELAN is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check TXMD's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, AYTU has a market cap of 19.6M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while AYTU trades at $1.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas AYTU's P/E ratio is -1.52. In terms of profitability, ELAN's ROE is -0.02%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, ELAN is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check AYTU's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ELAN's ROE is -0.02%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, ELAN is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check EVOK's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ELAN's ROE is -0.02%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, ELAN is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check ACRX's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, OPTH has a market cap of 12.9M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while OPTH trades at $2.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas OPTH's P/E ratio is -1.45. In terms of profitability, ELAN's ROE is -0.02%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, ELAN is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check OPTH's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ELAN's ROE is -0.02%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ELAN is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check AGRX's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, CABR has a market cap of 9.4M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while CABR trades at $1.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas CABR's P/E ratio is -1.32. In terms of profitability, ELAN's ROE is -0.02%, compared to CABR's ROE of -3.86%. Regarding short-term risk, ELAN is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check CABR's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ELAN's ROE is -0.02%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ELAN is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check NLTX's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, INM has a market cap of 8.1M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while INM trades at $15.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas INM's P/E ratio is -4.80. In terms of profitability, ELAN's ROE is -0.02%, compared to INM's ROE of -2.64%. Regarding short-term risk, ELAN is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check INM's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas LCI's P/E ratio is -0.04. In terms of profitability, ELAN's ROE is -0.02%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ELAN is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check LCI's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ELAN's ROE is -0.02%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ELAN is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ADMP's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, SBFM has a market cap of 5.8M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while SBFM trades at $2.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas SBFM's P/E ratio is -0.45. In terms of profitability, ELAN's ROE is -0.02%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, ELAN is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check SBFM's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, SNOA has a market cap of 5.3M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while SNOA trades at $1.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas SNOA's P/E ratio is -1.00. In terms of profitability, ELAN's ROE is -0.02%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, ELAN is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check SNOA's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas MNK's P/E ratio is -0.44. In terms of profitability, ELAN's ROE is -0.02%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ELAN is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check MNK's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, YCBD has a market cap of 4.5M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while YCBD trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas YCBD's P/E ratio is -0.99. In terms of profitability, ELAN's ROE is -0.02%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ELAN is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check YCBD's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ELAN's ROE is -0.02%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ELAN is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check FLGC's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, SBFMW has a market cap of 4.2M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while SBFMW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas SBFMW's P/E ratio is N/A. In terms of profitability, ELAN's ROE is -0.02%, compared to SBFMW's ROE of -0.24%. Regarding short-term risk, ELAN is more volatile compared to SBFMW. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check SBFMW's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, GELS has a market cap of 4M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while GELS trades at $0.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas GELS's P/E ratio is -1.00. In terms of profitability, ELAN's ROE is -0.02%, compared to GELS's ROE of -0.36%. Regarding short-term risk, ELAN is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check GELS's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ELAN's ROE is -0.02%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ELAN is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ELAN.Check PLXP's competition here

Elanco Animal Health Incorporated (NYSE: ELAN) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ELAN stands at 12.8B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ELAN is priced at $25.74 on the NYSE, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ELAN currently has a P/E ratio of 24.26, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ELAN's ROE is -0.02%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ELAN is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ELAN.Check ATNX's competition here